Astrana Health (NASDAQ:ASTH) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research cut shares of Astrana Health (NASDAQ:ASTH) from a hold rating to a strong sell rating in a research note released on Tuesday morning,Zacks.com reports.

Several other research firms have also recently commented on ASTH. TD Cowen cut their price target on Astrana Health from $40.00 to $35.00 and set a “buy” rating for the company in a report on Monday, November 10th. Barclays lowered their price objective on shares of Astrana Health from $36.00 to $26.00 and set an “equal weight” rating for the company in a research note on Monday, November 24th. BTIG Research cut their price target on Astrana Health from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Weiss Ratings restated a “sell (d+)” rating on shares of Astrana Health in a report on Monday, December 29th. Finally, Needham & Company LLC assumed coverage on Astrana Health in a report on Friday, December 12th. They issued a “buy” rating and a $28.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Astrana Health has an average rating of “Moderate Buy” and a consensus price target of $40.78.

Astrana Health Stock Down 1.2%

Shares of ASTH opened at $19.03 on Tuesday. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of 100.16, a PEG ratio of 0.57 and a beta of 0.90. Astrana Health has a 52 week low of $18.43 and a 52 week high of $39.97. The stock’s 50-day moving average price is $24.22 and its 200-day moving average price is $26.71. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.27.

Hedge Funds Weigh In On Astrana Health

Large investors have recently modified their holdings of the company. Ameriprise Financial Inc. lifted its position in Astrana Health by 231.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 442,314 shares of the company’s stock worth $12,540,000 after acquiring an additional 308,665 shares in the last quarter. 325 Capital LLC lifted its holdings in shares of Astrana Health by 34.6% in the 3rd quarter. 325 Capital LLC now owns 1,193,953 shares of the company’s stock worth $33,849,000 after purchasing an additional 307,037 shares during the last quarter. Pacer Advisors Inc. acquired a new position in shares of Astrana Health during the third quarter valued at $5,157,000. 1492 Capital Management LLC bought a new position in Astrana Health in the 4th quarter worth approximately $4,162,000. Finally, Insight Wealth Strategies LLC acquired a new position in shares of Astrana Health during the fourth quarter valued at $3,514,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.